On November 26, Glonny announced that Hefei Qunxiangqiming Enterprise Management Partnership Enterprise (Limited Partnership) controlled by the company signed the "Shenzhen Songhe Cell and Genetic Industry Private Equity Fund Partnership Enterprise (Limited Partnership) Partnership Agreement" and related documents with Shenzhen Songhe Capital Management Co., Ltd. on November 22, 2024. Qunxiangqiming, as a limited partner, subscribed 10 million yuan to the Shenzhen Songhe Cell and Genetic Industry Private Equity Fund Partnership Enterprise (Limited Partnership) (tentative name, subject to the name approved by the industrial and commercial registration authority, referred to as the "partnership") with a contribution ratio of 0.67%. The partnership's main investment projects include cell and gene therapy, new virus vectors, research and industrialization of new vaccines, genetic technologies, biological breeding research and industrialization, and upstream industries required in these areas.